Blog: Aging as an Engineering Problem
How Integrated Biosciences will make aging treatable
For most of human history, aging has been regarded as a fundamental biological constant. Beginning around the third decade of life, human mortality increases exponentially, with the hazard rate doubling approximately every eight years. This relationship, formalized as Gompertz’s law, has been one of the most reproducible observations in demography and biogerontology, reinforcing the view that aging reflects an intrinsic, irreversible process hard-wired into biology.
It isn’t.
Certain species, including tortoises, naked mole-rats (Heterocephalus glaber), Greenland sharks (Somniosus microcephalus), long-lived rockfish (Sebastes spp.), and the biologically immortal jellyfish (Turritopsis dohrnii), show negligible or even no increases in mortality risk with age. Evolution has arrived at extreme longevity and sustained healthspan multiple times across distantly related lineages. This single fact changes everything: aging is not an unavoidable descent into entropy, but a solvable biological failure mode—one that nature has already engineered solutions for in specific species.
Humans never got the full upgrade package. The force of natural selection drops sharply once reproductive success and the survival of grandchildren are secured (the so-called “grandmother effect”). As a result, our DNA repair, protein-quality-control, and inflammation-regulation circuits (among others) are “good enough” to reach 50–70 in the wild and then progressively fail. The good news is that “good enough” leaves significant room for biomedical intervention.
Figure 1. Most species follow Gompertz’s law. Several, such as the naked mole-rat, do not, which suggests that extreme longevity is biologically possible. Adapted from a recent article.
Strikingly, human biology already contains evidence that such engineering is possible. Every human begins life at a biological age of zero: during early embryogenesis, epigenetic aging markers are wiped clean within hours, erasing parental age entirely. Yamanaka’s discovery of reprogramming factors later showed that this reset can be triggered artificially. Recent studies now demonstrate that short, partial pulses of just three factors (OSK) can restore youthful DNA-methylation patterns, reverse glaucoma and age-related vision loss, reduce fibrosis and mesenchymal drift, and extend lifespan in accelerated-aging models. At the molecular level, aging is revealing itself not as destiny, but as an addressable engineering problem.
Our three-pronged strategy for discovering anti-aging therapies
To systematically address these interconnected failure modes, the discovery engine for aging therapies must be equally multifaceted. At Integrated, we deploy three complementary discovery modes to identify novel small-molecule therapeutics targeting aging and age-related disease. Being able to use all three strategies mitigates the weaknesses of any single approach and substantially increases the likelihood of finding true therapeutic winners. Most importantly, we’re already seeing these strategies translate into a rapidly advancing pipeline.
Focuses deeply on known aging pathways, like mTOR, senescence, or DNA damage, and tests whether precise modulation can slow aging or reduce pathology across multiple age-related diseases.
Optogenetic pathway-control systems and mechanistic predictions from advanced language models further sharpen this approach, increasing its resolution and specificity.
Strengths
Unmatched mechanistic clarity and precision; often underscores known targets or pathways with derisked and druggable biology.
Weaknesses
Prone to confirmation bias; it uncovers only what we already suspect and may overlook entirely new biology. May not suffice to capture the complexity of aging.
Casts a wide net by empirically testing many interventions in parallel, with minimal assumptions about which pathways matter. E.g. programs like the NIA Interventions Testing Program (ITP) have shown that systematic, multi-site mouse studies can identify true geroprotectors while weeding out non-reproducible claims.
Automation, high-throughput phenotyping, and better biomarkers are now making large-scale in vivo screening increasingly feasible. Broad screens can both surface unexpected hits and highlight convergent mechanisms, guarding against tunnel vision and expanding the therapeutic landscape.
Strengths
Low bias; broad discovery; identifies hidden opportunities.
Weaknesses
Potentially costly; noisy; requires strong validation pipelines.
Pushes breadth to the limit by using high-throughput experiments and AI to discover aging interventions without predefined hypotheses. Examples include high-content phenotypic screens where thousands of compounds are tested on aged cells or iPSC-derived organoids, with machine-learning classifiers detecting whether treated cells “look younger.”
Because this approach assumes no specific target or pathway, it can surface entirely new mechanisms. Foundation models trained on multi-omics datasets may further highlight pathways associated with healthy aging and propose new targets.
Strengths
Maximal breadth; low bias; uncovers mechanisms and interventions that humans would not predict.
Weaknesses
Requires substantial mechanistic follow-up.
From treating diseases to treating aging itself
A century ago, cancer was a death sentence. Today, many forms of cancer are chronic or curable because we have attacked the underlying biology systematically. Aging research is now at the same inflection point.
If we succeed—and the science increasingly indicates we can—the payoff is not merely a few extra years at life’s end, but decades of extended healthspan. Cardiometabolic disease, neurodegenerative disease, frailty, and most chronic illnesses will be compressed into a much smaller window, or prevented entirely.
The tools are here. We have invented new ways to make aging biology tractable. Progress now depends on execution.
Aging is an engineering problem.
We intend to solve it.
Max Wilson
CSO and Co-Founder